Core Insights - Harrow (HROW) reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of -140% [1] - The company generated revenues of $49.26 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 11.42%, but showing an increase from $34.27 million year-over-year [2] - Harrow's stock has increased by approximately 345.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 25.5% [3] Company Performance - Over the last four quarters, Harrow has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.50 on revenues of $81.8 million, and for the current fiscal year, it is $0.09 on revenues of $223.66 million [7] - The estimate revisions trend for Harrow is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - The article highlights the long-established efficacy and safety profile of topical cyclosporine, emphasizing its significance in ophthalmology [1] - The Total Pharma Tracker offers tools for DIY investors, including a software that provides extensive curated research material for various stocks [2][4] - The in-house experts at Total Pharma Tracker assist investors by identifying the best investable stocks and providing buy/sell strategies and alerts [3] Group 2 - The data presented shows significant cumulative growth percentages over the years, with a peak of 1212% and various other percentages indicating performance trends from 2017 to 2023 [2][4]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of a trend in short-term investing, highlighting that successful entry timing is crucial for capitalizing on price movements [1][2]. Group 1: Trend Analysis - The trend can reverse before exiting a trade, potentially leading to short-term capital losses for investors, necessitating confirmation of sound fundamentals and positive earnings estimates to maintain stock momentum [2]. - A unique short-term trading strategy, referred to as the "Recent Price Strength" screen, helps identify stocks with sufficient fundamental strength to sustain their recent uptrends [3]. Group 2: Stock Example - Harrow (HROW) - Harrow (HROW) has shown a solid price increase of 28.2% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - HROW has maintained a price increase of 0.5% over the past four weeks, suggesting that the upward trend is still intact [5]. - Currently, HROW is trading at 82% of its 52-week high-low range, indicating a potential breakout opportunity [6]. Group 3: Fundamental Strength - HROW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock also has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 4: Additional Opportunities - Besides HROW, there are several other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting potential investment opportunities [8]. - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles to identify winning stock picks [8].

The market expects Harrow (HROW) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 13, 2024, might help the stock move higher if these key numbers are ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 6th:Harrow, Inc. (HROW) : This eyecare pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 164.3% over the last 60 days.Harrow’s shares gained 108.4% over the last three months compared with the S&P 500’s advance of 11.1%. The company possesses a Momentum Score  of B.Orla Mining Ltd. (ORLA) : This mining company has a Zac ...

Investors might want to bet on Harrow (HROW) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a c ...

Shares of Harrow (HROW) have gained 5% over the past four weeks to close the last trading session at $47.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $59.45 indicates a potential upside of 26%.The mean estimate comprises four short-term price targets with a standard deviation of $12.23. While the lowest estimate of $44.80 indicates a 5.1% decline from the current price le ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

The healthcare sector is one of the largest in the U.S., with spending accounting for nearly one-fifth of the national economy, expected to reach nearly $4.9 trillion in 2024. The sector comprises some of the High Dividend Opportunities, #1 On Seeking Alpha High Dividend Opportunities: The Income Method Interested in arowing uour income? HDO is the largest and most exciting community of income investors and retirees with over +8000 members. We are looking for more members to join our lively group! Our Incom ...

Harrow (HROW) shares soared 8.4% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.8% gain over the past four weeks. Earlier this week, the company relaunched its ophthalmology drug, Triesence, which is approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. This might have driven the sha ...